Skip to main content
. 2020 Sep 29;10:15963. doi: 10.1038/s41598-020-73043-x

Table 1.

Sociodemographic data, clinical assessment and biomarkers, according to sex.[(mean, SD) or (N, %)].

Men
(n = 82; 62.1%)
Women
(n = 50; 37.9%)
Test (p)
Age 35.41 (11.52) 40.16 (12.35) t = − 2.234 (0.027)
Illness duration (years) 8.38 (9.01) 9.84 (12.11) t = − 0.787 (0.433)
Hospital admissions 1.66 (2.50) 1.40 (1.64) t = 0.583 (0.561)
BMI (kg/m2) 28.62 (5.66) 27.60 (5.80) t = 0.997 (0.321)
CPZeq (mg/day) 776.23 (551.69) 501.42 (539.41) t = 2.799 (0.006)
BZD treatment, n (%) 43 (52.4%) 19 (38.0%) Χ2 = 2.600 (0.107)
Smoking, n (%) 48 (58.5%) 17 (34.0%) Χ2 = 7.482 (0.006)
Clinical scales
PANSS positive 13.63 (5.34) 11.68 (5.24) t = 2.053 (0.042)
PANSS negative 19.39 (5.70) 16.96 (5.71) t = 0.993 (0.019)
PANSS GP 31.70 (8.00) 27.22 (7.90) t = 0.642 (0.002)
CAINS MAP 20.27 (9.47) 18.16 (10.21) t = 1.205 (0.230)
CAINS EXP 6.84 (4.10) 5.66 (4.50) t = 1.548 (0.124)
CDS 3.23 (3.95) 3.00 (4.24) t = 0.318 (0.751)
MCCB (T-scores)
Speed of processing 33.39 (18.36) 32.26 (11.52) t = 0.390 (0.697)
Attention/vigilance 34.55 (10.80) 34.62 (11.94) t = − 0.035 (0.973)
Working memory 38.80 (14.37) 40.61 (12.55) t = − 0.730 (0.467)
Verbal learning 38.84 (9.75) 41.96 (12.14) t = − 1.622 (0.107)
Visual learning 35.72 (14.04) 38.27 (14.35) t = − 0.996 (0.321)
Reasoning and problem solving 35.52 (9.61) 36.35 (7.35) t = − 0.551 (0.583)
Social cognition 43.46 (16.15) 47.69 (20.21) t = − 1.232 (0.222)
CRP (mg/dL) 0.33 (0.36) 0.37 (0.51) t = − 0.463 (0.645)
CRP > 0.3 mg/dL, n (%) 22 (26.8%) 13 (26.0%) Χ2 = 0.011 (0.917)

BMI: Body Mass Index, BZD: Benzodiazepines, CAINS: Clinical Assessment Interview for Negative Symptoms, -EXP: Expression subscale, -MAP: Motivation and Pleasure subscale, CDS: Calgary Depression Scale, CPZeq: Chlorpromazine equivalent, CRP: C-Reactive Protein; MCCB: MATRICS Consensus Cognitive Battery, PANSS: Positive and Negative Syndrome Scale, -GP: General Psychopathology.